Cannabinoid Receptor

Receptor

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Related Products (380)
Antibodies (1)
Cannabinoid Receptor Isoform Comparison

By Effects:	Controls (2) Inhibitors (31) Ligands (8) Agonists (112) Antagonists (61) Activators (11) Modulators (20) Chemical (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-107471

CB2 receptor agonist 3	Agonist	99.86%
CB2 receptor agonist 3 is a robust and selective CB2 cannabinoid agonist with K_is of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells.

HY-P1090

Hemopressin(rat)	Antagonist	99.86%
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models.

HY-126161

Nonabine	Activator	99.95%
Nonabine (BRL-4664), a cannabinoid, is a antiemetic agent. Nonabine activates CB1 receptor in the brainstem and enteric nervous system.

HY-120851

O-7460
O-7460 is a potent and selective DAGLα inhibitor, with an IC₅₀ of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels.

HY-103325

JTE-907	Modulator	98.72%
JTE-907 is a highly selective, orally active CB2 receptor inverse agonist and exerts anti-inflammatory effects in vivo.

HY-122964

URB447	Antagonist	99.5%
URB447 is a peripherally restricted CB₁ cannabinoid antagonist (IC₅₀: 313 nM and 41 nM for rat CB1 and human CB2 receptor respectively ). URB447 lowers food intake and body-weight gain in mice without entering the brain or antagonizing central CB₁-dependent responses. URB447 can be used for research of obesity.

HY-110040

L759633	Agonist	≥99.0%
L759633 is a potent and selective agonist of cannabinoid receptor (CB₂) receptor, with K_is of 6.4 nM and 1043 nM for CB2 and CB1 receptors, respectively. L759633 can inhibit Forskolin-stimulated cAMP production.

HY-162618

PSB-KK1445	Agonist	99.47%
PSB-KK1445 is a potent and selective GPR18 agonist with EC₅₀s of 45.4 nM and 124 nM for human and mouse GPR18, respectively. PSB-KK1445 displays >200-fold selectivity versus both CB receptor subtypes, GPR55, and GPR183.

HY-110018

N-Arachidonyldopamine	Agonist	98.36%
N-Arachidonyldopamine is a potent and selective endogenous CB1 receptor agonist with a K_i of 250 nM. N-Arachidonyldopamine is also a potent and selective TRPV1 agonist an with EC₅₀ of ~ 50 nM.

HY-103327

MJ15	Antagonist
MJ15 is a potent and selective CB1 receptor antagonist with a K_i of 27.2 pM and an IC₅₀ of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice.

HY-N1415S

β-Caryophyllene-d₂	Agonist
β-Caryophyllene-d₂ is deuterium labeled β-Caryophyllene. β-Caryophyllene is a CB2 receptor agonist.

HY-10863S

Anandamide-d₈	Agonist	99.90%
Anandamide-d8 is a deuterated labeled Anandamide. Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis.

HY-110179

PSNCBAM-1	Antagonist	99.48%
PSNCBAM-1 is a selective CB1 receptor allosteric antagonist with an EC₅₀ of 0.1 μM. PSNCBAM-1 can be used in the researches of obesity.

HY-W400424

(-)-6α-Hydroxy cannabidiol
(-)-6α-Hydroxy cannabidiol is a metabolite of Cannabidiol.

HY-124089S

Eicosapentaenoyl ethanolamide-d₄	Agonist	≥99.0%
Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant[1][2].

HY-10871A

Otenabant Hydrochloride	Antagonist
Otenabant Hydrochloride is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-15420

BML-190	Agonist	99.53%
BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).

HY-118641

Cannabinodiol
Cannabinodiol, a cannabinoid analogue, is a phytocannabinoid.

HY-141411A

Zevaquenabant	Antagonist	99.62%
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD).

HY-112707

AM9405	Agonist
AM9405 is a novel peripherally active cannabinoid type 1 (CB1) and serotonin type 3 receptor agonist. AM9405 inhibits twitch contraction of the ileum and the colon with IC₅₀s of 45.71 and 0.076 nM, respectively.

Anandamide	CB1	CB2	≥99.0%
Rimonabant	CB1 , Ki: 1.8 nM		99.18%
Pregnenolone	CB1		99.87%
SR144528		CB2	99.25%
JD-5037	CB1 , IC₅₀: 1.5 nM		99.38%
Rimonabant Hydrochloride	CB1 , Ki: 1.8 nM		99.79%
Pregnenolone monosulfate sodium	CB1		99.96%
Synaptamide	CB1 , Ki: 633 nM	CB2 , Ki: 3843 nM	99.30%
Leelamine	CB1	CB2	98.36%
Yangonin	CB1 , IC₅₀: 1.79 μM CB1 , Ki: 0.72 μM		99.79%
N-Oleoyl glycine	CB1		≥99.0%
GW-405833	CB1 , EC₅₀: 16.1 μM	CB2 , EC₅₀: 50.7 nM	99.12%
Pregnenolone monosulfate	CB1		99.22%
AM281	CB1 , IC₅₀: 9.91 nM	CB2 , IC₅₀: 13000 nM	≥99.0%
Leelamine hydrochloride	CB1		99.06%
Etrinabdione		CB2	99.16%
CB2R PAM		cannabinoid type-2 receptors	98.46%
CB1 antagonist 4	CB1		99.00%
Tetrahydromagnolol	CB1 , EC₅₀: 9010 nM CB1 , Ki: 2260 nM	CB2 , EC₅₀: 170 nM CB2 , Ki: 416 nM	99.79%
SCH 336		hCB2-R	98.85%
Bay 59-3074	CB1 , Ki: 48.3 nM	CB2 , Ki: 45.5 nM	98.60%
CB1/2 agonist 3	hCB1-R, Ki: 5.9 nM	hCB2-R, Ki: 3.5 nM	99.83%
AZD1940	hCB1-R, pKi: 7.93	hCB2-R, pKi: 9.06	99.58%
CB1/2 agonist 1	hCB1-R, EC₅₀: 56.15 nM	cannabinoid type-2 receptors, EC₅₀: 11.63 nM	99.20%
Drinabant	hCB1-R, IC₅₀: 25 nM rCB1-R, IC₅₀: 10 nM	CB2 , IC₅₀: 10000 nM	≥99.0%
GW 833972A		hCB2-R, pEC₅₀: 7.3 rat CB2-R, pEC₅₀: 7.5	99.91%
Pregnenolone (Standard)	CB1
GAT211	CB1		99.98%
Auriculasin	CB1 , IC₅₀: 8.92 μM		98.58%
Tedalinab		CB2	99.94%
(R)-Methanandamide	CB1 , Ki: 20 nM
CB2R antagonist 3		CB2R	98.08%
Ibipinabant	CB1 , Ki: 7.8 nM	CB2 , Ki: 7943 nM	99.90%
CB2 modulator 1		CB2	99.75%
PGN36		cannabinoid type-2 receptors, Ki: 0.09 μM	99.74%
2-Palmitoylglycerol	CB1		≥99.0%
RVD-Hpα TFA	CB1		99.32%
ANEB-001	CB1
Noladin ether	CB1 , Ki: 21.2 nM	CB2 , Ki: >3 mM	≥98.0%
CB2R/FAAH modulator-3	CB1 , Ki: 67.6 nM	CB2 , Ki: 20.1 nM	99.71%
CB2 receptor agonist 2		CB2 , Ki: 8.5 nM	≥99.0%
Nonabine	CB1		99.95%
URB447	CB1 , IC₅₀: 313 nM		99.5%
L759633	CB1 , Ki: 1043 nM	CB2 , Ki: 6.4 nM	≥99.0%
N-Arachidonyldopamine	CB1 , Ki: 250 nM		98.36%
MJ15	rCB1-R, Ki: 27.2 pM rCB1-R, IC₅₀: 118.9 pM
PSNCBAM-1	hCB1-R, EC₅₀: 0.1 μM		99.48%
Zevaquenabant	CB1		99.62%
AM9405	CB1 , IC₅₀: 45.71 nM
Isopropyl dodec-11-enylfluorophosphonate	CB1 , IC₅₀: 2 μM
(R)-SLV 319	CB1 , Ki: 894 nM
RTICBM-189	CB1 , pIC₅₀: 7.54 hCB₁, pIC₅₀: 5.29 mCB₁, pIC₅₀: 6.25		99.73%
CB2 receptor agonist 9		CB2R, EC₅₀: 16.2 nM
AChE/BChE-IN-18		CB2 , Ki: 31 nM
LY320135	CB1 , Ki: 141 nM	CB2 , Ki: >10 μM
Dihomo-γ-Linolenoyl Ethanolamide	hCB1-R, Ki: 857 nM	hCB2-R, Ki: 598 nM
O-2050	CB1 , Ki: 2.5 nM	CB2 , Ki: 0.2 nM
CB2 receptor agonist 8		CB2R
CB1R agonist 1	CB1R, Ki: 0.95 nM
Tocrifluor 1117	CB1
CB1R Allosteric modulator 4	hCB1-R
hBChE-IN-2		hCB2-R, IC₅₀: 0.78 μM
BAY 38-7271	CB1 , Ki: 1.85 nM	CB2 , Ki: 5.96 nM
CB2R-IN-1		CB2 , Ki: 0.9 nM
CB1R Allosteric modulator 3	CB1		98.05%
CB2R agonist 3		CB2R, EC₅₀: 0.37 μM
PSB-SB-1203	CB1 , Ki: 0.244 μM	CB2 , Ki: 0.21 μM
SMM-189		CB2
MDA7	rCB1-R, Ki: 2565 nM	rat CB2-R, IC₅₀: 67.4 nM hCB2-R, IC₅₀: 128 nM rat CB2-R, Ki: 238 nM hCB2-R, Ki: 422 nM
MN-25	CB1 , Ki: 254 nM	CB2 , Ki: 11 nM
CB1/2 receptor-1	CB1	CB2
CBR Agonist-2	hCB1-R, EC₅₀: 960 nM hCB1-R, Ki: 970 nM
CB2R probe 1		cannabinoid type-2 receptors, Ki: 130 nM
(R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide	CB1 , Ki: 21 μM	CB2 , Ki: 21 μM
CB2 receptor agonist 6		CB2R
CB2R/FAAH modulator-2	CB1 , Ki: 152.9 nM	CB2 , Ki: 10.8 nM
Docosatetraenylethanolamide	CB1
CB2R agonist 1		CB2R, EC₅₀: 0.56 μM
R-2 Methanandamide	rCB1-R, Ki: 119 nM
TRPV1/CB2 agonist 1		CB2
Amauromine	CB1 , Ki: 178 nM CB1 , Kb: 66.6 nM
CB1R antagonist 1	hCB1-R, IC₅₀: 4.2 μM hCB1-R, EC₅₀: 10 μM		99.89%
CB1 inverse agonist 2	CB1 , pKi: 9.7	CB2 , pKi: 6.0
rel-O-2050	CB1
CB2R/FAAH modulator-1	CB1R, Ki: 241.3 nM CB1R, EC₅₀: 489 nM	CB2R, Ki: 14.8 nM CB2R, EC₅₀: 123.6 nM
AZD-2207	CB1
CB1/2 agonist 2	hCB1-R, Ki: 3.5 nM	hCB2-R, Ki: 1.2 nM
CB1R Allosteric modulator 2	hCB1-R
CB1R Allosteric modulator 1	hCB1-R
Δ9-THCB	CB1 , Ki: 15 nM	CB2 , Ki: 51 nM
Mead ethanolamide	CB1 , Kd: 753 nM	CB2 , Kd: 1810 nM
PM226		CB2 , Ki: 13 nM CB2 , EC₅₀: 39 nM
NIDA-41020	CB1 , Ki: 4.1 nM
RVD-Hpα	CB1
CBR Agonist-1	rCB1-R, Ki: 0.18 μM	hCB2-R, Ki: 1.22 μM
AB-FUBICA	CB1 , EC₅₀: 21 nM	CB2 , EC₅₀: 15 nM
MRL-650	CB1 , IC₅₀: 7.5 nM	CB2 , IC₅₀: 4100 nM
Eicosapentaenoyl ethanolamide	CB1	CB2
CB1-IN-2	CB1 , IC₅₀: 0.644 μM
CB1 antagonist 5	hCB₁, EC₅₀: 195 nM hCB₁, Ki: 243 nM
Δ8-THC-C8	CB1 , EC₅₀: 13.8 nM
Δ8-THC methyl ether		CB2
PF-03550096		CB2 , Ki: 7.9 nM
TM38837	CB1
PSB-SB1202	CB1 , EC₅₀: 56 nM CB1 , Ki: 32 nM	CB2 , EC₅₀: 14 nM CB2 , Ki: 49 nM
Δ8-THCP	CB1

Name
Email *

	Sorry, but the email address you supplied was invalid.

Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Related Products (380)

Antibodies (1)

Cannabinoid Receptor Isoform Comparison

Cannabinoid Receptor Related Products (380):